Search

Your search keyword '"Boettcher, S."' showing total 91 results

Search Constraints

Start Over You searched for: Author "Boettcher, S." Remove constraint Author: "Boettcher, S." Database OAIster Remove constraint Database: OAIster
91 results on '"Boettcher, S."'

Search Results

1. A reappraisal of explosive–effusive silicic eruption dynamics:syn-eruptive assembly of lava from the products of cryptic fragmentation

2. A reappraisal of explosive–effusive silicic eruption dynamics : syn-eruptive assembly of lava from the products of cryptic fragmentation

3. Energetic ions in the Venusian system : Insights from the first Solar Orbiter flyby

4. The first widespread solar energetic particle event observed by Solar Orbiter on 2020 November 29

5. Energetic ions in the Venusian system : Insights from the first Solar Orbiter flyby

6. The first widespread solar energetic particle event observed by Solar Orbiter on 2020 November 29

7. The first widespread solar energetic particle event observed by Solar Orbiter on 2020 November 29

8. Energetic ions in the Venusian system : Insights from the first Solar Orbiter flyby

9. Energetic ions in the Venusian system : Insights from the first Solar Orbiter flyby

10. The first widespread solar energetic particle event observed by Solar Orbiter on 2020 November 29

11. Energetic ions in the Venusian system : Insights from the first Solar Orbiter flyby

12. The first widespread solar energetic particle event observed by Solar Orbiter on 2020 November 29

13. Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia

14. Signal quality and patient experience with wearable devices for epilepsy management

15. Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia

16. Fixed-duration venetoclax plus obinutuzumab improves pfs and minimal residual disease negativity in patients with previously untreated CLL and comorbidities.

17. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions.

18. Fixed-duration venetoclax plus obinutuzumab improves pfs and minimal residual disease negativity in patients with previously untreated CLL and comorbidities.

19. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions.

20. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

21. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions

22. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions

23. Comparison of 3 different phase II studies using sequential combinations of targeted agents to treat chronic lymphocytic leukemia

24. B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide

25. B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide

26. Comparison of 3 different phase II studies using sequential combinations of targeted agents to treat chronic lymphocytic leukemia

27. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial

28. Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial

29. Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial

30. Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial

32. CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial

33. QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY

34. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

35. CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group

36. CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial

37. QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY

38. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab

39. CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group

40. WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS

41. CLL2-BIG, -BAG, -BCG and -BIO: A series of four phase-II trials evaluating a sequential regimen of combined targeted therapy aiming for a total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia (CLL)

42. Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)

43. WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS

44. CLL2-BIG, -BAG, -BCG and -BIO: A series of four phase-II trials evaluating a sequential regimen of combined targeted therapy aiming for a total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia (CLL)

45. Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG)

46. Long Term Remissions After FCR Chemoimmunotherapy In Patients With CLL

47. Screening supported by a central review allows a precise selection of the population for maintenance therapy within the CLLM1 trial of the German CLL Study Group

48. SEVERE INFECTIONS ARE MORE COMMON IN PHYSICALLY FIT CLL PATIENTS WITH FCR-THERAPY COMPARED TO BR: RESULTS OF THE INTERMIN-ANALYSIS OF THE CLL10 TRIAL OF THE GERMAN CLL STUDY GROUP

49. CENTRAL SCREENING ENABLES IDENTIFICATION OF HIGH RISK CLL PATIETNS FOR LENALIDOMIDE MAINTENANCE THERAPY WITHIN THE CLLM1 TRIAL OF THE GERMAN CLL STUDY GROUP

50. More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group

Catalog

Books, media, physical & digital resources